^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    JNJ-8543

    i
    Other names: JNJ-8543, JNJ-80948543, JNJ80948543, JNJ8543, JNJ 80948543, JNJ 8543
    Associations

    News

    Trials
    Company:
    J&J
    Drug class:
    CD20 inhibitor, CD3 agonist, CD79B inhibitor
    Related drugs:
    Associations

    News

    Trials
    24d
    A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL) (clinicaltrials.gov)
    P1, N=19, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting | N=40 --> 19
    Enrollment closed • Enrollment change
    |
    JNJ-8543 • rezetamig (JNJ-8780)
    5ms
    A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
    P1, N=167, Active, not recruiting, Janssen Research & Development, LLC | Recruiting --> Active, not recruiting | Trial completion date: Nov 2026 --> Jul 2027
    Enrollment closed • Trial completion date
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    JNJ-8543
    5ms
    A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer (clinicaltrials.gov)
    P1, N=235, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: Jul 2026 --> Nov 2027
    Trial primary completion date
    |
    JNJ-8543 • rezetamig (JNJ-8780)
    6ms
    A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer (clinicaltrials.gov)
    P1, N=235, Recruiting, Janssen Research & Development, LLC | N=70 --> 235 | Trial completion date: Jul 2026 --> Nov 2027
    Enrollment change • Trial completion date
    |
    JNJ-8543 • rezetamig (JNJ-8780)
    1year
    A Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R B-Cell NHL) (clinicaltrials.gov)
    P1, N=40, Recruiting, Janssen Research & Development, LLC
    New P1 trial • Combination therapy
    |
    JNJ-8543 • rezetamig (JNJ-8780)
    over1year
    A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
    P1, N=220, Recruiting, Janssen Research & Development, LLC | Trial primary completion date: Jul 2024 --> Jun 2026
    Trial primary completion date • Trispecific
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    JNJ-8543
    almost2years
    A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer (clinicaltrials.gov)
    P1, N=70, Recruiting, Janssen Research & Development, LLC | Not yet recruiting --> Recruiting | Trial completion date: Jul 2028 --> Jul 2026
    Enrollment open • Trial completion date • Combination therapy
    |
    JNJ-8543 • rezetamig (JNJ-8780)
    almost2years
    A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
    P1, N=180, Recruiting, Janssen Research & Development, LLC | Trial completion date: Oct 2024 --> Oct 2026
    Trial completion date • Trispecific
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    JNJ-8543
    2years
    A Study of JNJ-87801493 in Combination With T-Cell Engagers in Participants With B-cell Non-Hodgkin Lymphoid (NHLs) Cancer (clinicaltrials.gov)
    P1, N=70, Not yet recruiting, Janssen Research & Development, LLC
    New P1 trial • Combination therapy
    |
    JNJ-8543 • rezetamig (JNJ-8780)
    over2years
    A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
    P1, N=180, Recruiting, Janssen Research & Development, LLC | Trial completion date: Jul 2024 --> Oct 2024
    Trial completion date • Trispecific
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    JNJ-8543
    over2years
    A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (clinicaltrials.gov)
    P1, N=180, Recruiting, Janssen Research & Development, LLC | Trial completion date: Jan 2025 --> Jul 2024 | Trial primary completion date: Jan 2025 --> Jul 2024
    Trial completion date • Trial primary completion date • Trispecific
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    JNJ-8543
    3years
    Characterization of JNJ-80948543, a Novel CD79bxCD20xCD3 Trispecific T-Cell Redirecting Antibody for the Treatment of B-Cell Non-Hodgkin Lymphoma (ASH 2022)
    Taken together, JNJ-80948543 is a potential first-in-class trispecific antibody for the treatment of B‑NHL malignancies with high unmet medical needs. A Phase I dose-escalation study of JNJ-80948543 in patients with relapsed/refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia (CLL) will be initiated.
    IO biomarker
    |
    CD79B (CD79b Molecule)
    |
    JNJ-8543